Vaccine Development

Oct 09, 2007
BioPharm International
By BioPharm International Editors
The US Food and Drug Administration has approved the use of the nasal influenza vaccine FluMist in children ages 2?5.
Oct 09, 2007
BioPharm International
By BioPharm International Editors
The approval of a new seasonal influenza vaccine has further diversified the supply to the US market.
Oct 01, 2007
BioPharm International
By BioPharm International Editors
It is hoped that HIV patients' own immune responses can be strengthened by vaccines so they will not have to rely exclusively on antiretroviral drugs.
Aug 02, 2007
BioPharm International
By BioPharm International Editors
Adjuvant-caused vaccine reactions are one of the most important barriers to better acceptance of routine prophylactic vaccination.
Aug 02, 2007
BioPharm International
By BioPharm International Editors
Like the egg-based vaccine production process, producing a vaccine under cGMP conditions using mammalian cells can be a lengthy process, taking a minimum of six to 12 months.
Aug 02, 2007
BioPharm International
Any endpoint considered appropriate to support approval, whether a surrogate or a clinical endpoint, must be supported by substantial evidence of effectiveness.
Aug 02, 2007
BioPharm International
By BioPharm International Editors
Vaccines against strains originating from avian flu may achieve poor yields in egg-based systems. Consequently, both public and private interest in alternative systems is high.
Aug 02, 2007
BioPharm International
By BioPharm International Editors
The recent growth in the vaccine market has led to renewed interest in using adherent human cell lines for vaccine production. Traditionally, small-scale adherent cell line production has been carried out in roller bottles or T-flasks. Over the past few years, however, a number of companies have found multi-tray disposable bioreactors an effective method for producing high-quality drug products using adherent cells. These disposable, expandable systems have also facilitated scale up from laboratory to clinical-scale.
Aug 02, 2007
BioPharm International
By BioPharm International Editors
For many cell-based vaccines, the precursor monocytes or CD34+ cells are cultured with cytokines to obtain dendritic cells, which are very potent antigen-presenting cells (APCs).
Aug 02, 2007
BioPharm International
By BioPharm International Editors
In animal studies, we have demonstrated that the dose of an injected H5N1 vaccine candidate can be significantly reduced by using a skin patch containing E. coli heat-labile enterotoxin (LT) applied over the injection site. LT-activated epidermal Langerhans cells migrate to the nearby draining lymph node and enhance the immune response to the injected antigen. A dry patch formulation has been optimized as a dose sparing strategy for pandemic flu and other vaccines. Iomai Corporation has developed a proprietary stabilizing formulation for the patch that allows use and storage at ambient temperature. The patch withstands temperature extremes during shipment, and is suitable for stockpiling.
native1_300x100
lorem ipsum